EMA Proposes Decision Tree Approach to Environmental Risk Assessments

Drug Industry Daily
The EMA’s Committee for Medicinal Products for Human Use released draft guideline on environmental risk assessments for human drugs — including decision trees to help sponsors decide if they need a Phase I, Phase II or customized risk assessment.

To View This Article:


Subscribe To Drug Industry Daily